Compare SLNG & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLNG | ADAG |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.4M | 222.2M |
| IPO Year | 2019 | 2020 |
| Metric | SLNG | ADAG |
|---|---|---|
| Price | $5.00 | $2.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.91 |
| AVG Volume (30 Days) | 20.8K | ★ 277.3K |
| Earning Date | 11-04-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2400.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $68,245,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $70.23 | $129.59 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.21 | $1.44 |
| 52 Week High | $7.07 | $4.85 |
| Indicator | SLNG | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 34.86 |
| Support Level | $4.79 | $2.80 |
| Resistance Level | $5.52 | $3.19 |
| Average True Range (ATR) | 0.27 | 0.29 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 37.09 | 16.77 |
Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. The company has a geographical presence in the United States and Mexico.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.